Completed
A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
I9S-MC-BTAB - ClinicalTrials.gov - NCT03933943
The main purpose of this study is to learn more about the safety of LY3361237 and any side effects that might be associated with it when given to participants with systemic lupus erythematosis (SLE). LY3361237 will be administered by injections just under the skin.
How long will I be in the trial?
The study will last up to 26 weeks and may include up to 17 visits to the study center.
Completed
A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
I9S-MC-BTAB - ClinicalTrials.gov - NCT03933943
The main purpose of this study is to learn more about the safety of LY3361237 and any side effects that might be associated with it when given to participants with systemic lupus erythematosis (SLE). LY3361237 will be administered by injections just under the skin.
How long will I be in the trial?
The study will last up to 26 weeks and may include up to 17 visits to the study center.
Key Requirements
Age :
18-70
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18-70
Sex
All
Participants must
Participants must have been diagnosed with SLE at least 6 months before enrollment
Participants taking an oral steroid called prednisone (or equivalent) must be taking no more than 20 milligrams for at least 2 months and must be on a stable dose.
Participants taking other common medications for SLE must be on the medication for at least 3 months with a stable dose for at least 2 months.
Participants must NOT
Participants must not have or have had any other diseases that cause inflammation of the joints or skin.
Participants must not have an active infection.
Participants must not have serious liver or kidney dysfunction.
Participants must not have taken medications to destroy cancer cells within the last 3 months
Participants must not have had a blood transfusion within the last year.
Trial Summary
Conditions the trial is for
Lupus (SLE)
What the trial is testing?
LY3361237, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
24
Trial Dates
May 2019 - February 2021
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18-70
Sex
All
Participants must
Participants must have been diagnosed with SLE at least 6 months before enrollment
Participants taking an oral steroid called prednisone (or equivalent) must be taking no more than 20 milligrams for at least 2 months and must be on a stable dose.
Participants taking other common medications for SLE must be on the medication for at least 3 months with a stable dose for at least 2 months.
Participants must NOT
Participants must not have or have had any other diseases that cause inflammation of the joints or skin.
Participants must not have an active infection.
Participants must not have serious liver or kidney dysfunction.
Participants must not have taken medications to destroy cancer cells within the last 3 months
Participants must not have had a blood transfusion within the last year.
Trial Summary
Conditions the trial is for
Lupus (SLE)
What the trial is testing?
LY3361237, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
24
Trial Dates
May 2019 - February 2021
Trial Phase
1
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Lupus (SLE) Resources
